US Pharma MarketingASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
Source: FiercePharma